Phase 4 N=64 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure
Closure of Vaginal Cuff at Laparoscopic Hysterectomy
Primary: Vaginal Cuff Closure Time — 10.4; 9.6 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=120 Vaginal Cuff Dehiscence and Thermal Injury During TLH
Vaginal Cuff Dehiscence · Thermal Injury
Primary: Degree of Thermal Injury at the Time of Laparoscopic Hysterectomy — 0.68; 0.63; 0.66; 0.70 mm
N/A N=168 Long Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure
Cesarean Section; Complications · Placenta Previa · Placenta Accreta
Primary: Placenta Previa — 18; 17; 0; 3 Participants
N/A N=168 Short Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure
Cesarean Section Complications
Primary: Cesarean Scar Defect in the Uterine Incisional Line — 12; 39 participants — p=0.0001
N/A N=282 Single or Double-layer Uterine Closure Techniques
Uterine Scar · Cesarean Section Complications · Cesarean Section; Dehiscence
Primary: Number of Participants With Niche Visualized by Saline Infusion Sonography — 40; 53; 25; 23 Participants — p=0.05
N/A N=49 Vaginally Assisted Laparoscopic Hysteropexy Versus Vaginal Hysterectomy
Pelvic Organ Prolapse
Primary: Number of Participants With Recurrence of Pelvic Organ Prolapse — 0; 0 Participants
N/A N=318 Rapidly Absorbing Polyglactin 910 Versus Poliglecaprone 25 for Laceration Repair
Dyspareunia · Perineal Tear · Sutured Laceration
Primary: Rates of Dyspareunia — 3.6; 3.49 units on a scale — p=0.16
N/A N=57 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?
Uterine Fibroids · Abnormal Uterine Bleeding · Pelvic Pain
Primary: Vaginal Cuff Closure Times — 10.17; 12.54 minutes
Phase 4 N=14 ABRA Abdominal Closure System in Open Abdomen Management
Open Abdomen
Primary: Primary Closure Rate — 75; 67 % of participants
N/A N=124 Modified "Open Intraperitoneal Mesh" Technique of Incisional Ventral Hernia Repair
Incisional Ventral Hernia · Recurrent Ventral Hernia
Primary: Number of Early Postoperative Complications (Wound Infections, Seroma, Hematoma) — 9; 21; 2; 92 participants
Phase 4 N=550 Subcuticular Suture for Cesarean Skin Incision Closure
Complications; Cesarean Section · Surgical Wound Infection
Primary: Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc) — 23; 37; 16; 25 Participants — p=0.04
Phase 2 N=165 Randomized Clinical Trial of Skin Closure With Staples Versus Suture
Wound Infection · Wound Complication
Primary: Number of Participants With Wound Disruption or Infection (Wound Complications) Occurring Within 4-8 Weeks of the Date of the Primary Surgery. — 28; 25 Participants
N/A N=72 Barbed Suture Versus Non-Barbed Suture for Posterior Colporrhaphy
Rectocele
Primary: Post-operative Posterior Compartment Pain Scores - Posterior Repair — 32; 29; 2; 4 Participants — p=0.32
N/A N=746 Cesarean Trial of Staples vs. Sutures
Cesarean Section · Wound Complications · Patient Satisfaction
Primary: Number of Participants With Wound Complications — 18; 40; 9; 14 Participants
N/A N=236 Apical Support During Hysterectomy for Pelvic Organ Prolapse
Pelvic Organ Prolapse
Primary: Proportion of Patients Having Concurrent Apical Suspension Performed — 66 Participants
N/A N=18 Vacuum Assisted Therapy in Emergent Contaminated Abdominal Surgeries
Gastrointestinal Injury · Complicated Diverticulitis
Primary: Rate of Surgical Site Infection — 5 Participants
N/A N=48 A Long Term Follow up of Anterior Meshes for Recurrent Prolapse
Genital Diseases, Female · Pelvic Organ Prolapse
Primary: The Number of Participants With a Current Mesh Erosion or Treated for a Mesh Erosion Since Inserted — 5 Participants
N/A N=112 Stoma Closure and Reinforcement Trial
Colon Cancer · Rectal Cancer · Ileostomy - Stoma
Primary: Number of Participants With Wound Occurrences — 0 Participants
N/A N=204 Permanent Versus Absorbable Colpopexy Trial
Pelvic Organ Prolapse
Primary: Number of Participants With Vaginal Mesh or Suture Exposure — 5; 8 Participants — p=0.30
N/A N=4 Efficacy Study to Evaluate Laparoscopic Fascial Closure Device
Hernia, Abdominal
Primary: Count of Participants With Successful Port Site Closure Using Port Close Device — 3 Participants
N/A N=110 Negative Pressure Wound Therapy After Cesarean Delivery
Major Puerperal Infection, Postpartum · Wound Complications · Wound Seroma
Primary: Wound Complication Rate — 3; 1; 3; 6 participants
N/A N=226 Barbed Suture for Hysterotomy Closure During Cesarean Section
Hysterotomy
Primary: Quantitative Blood Loss — 641.8; 596.5 mL
N/A N=713 Xenform Postmarket Surveillance Study
Pelvic Organ Prolapse
Primary: Number of Participants With Success at 36 Months — 191; 390 Participants
N/A N=113 Same Day Discharge After Minimally-invasive Sacrocolpopexy
Pelvic Organ Prolapse
Primary: Number of Participants* With Serious Adverse Events — 4; 3 Participants
N/A N=99 Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Anterior Vaginal Wall Prolapse · Cystocele · Pelvic Organ Prolapse
Primary: Prospective Randomized Trial of Anterior Colporrhaphy Vs. Cystocele Repair Using Polypropylene Mesh or Porcine Dermis — 5; 14; 12 Participants
N/A N=9 SurgiMend Mesh at the Hiatus
Hiatal Hernia
Primary: Recurrence Rate — 6; 3 Participants
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Phase 2 N=337 Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling Trial
Pelvic Organ Prolapse
Primary: Number of Participants With Treatment Failure Defined as Subsequent Treatment for Urinary Incontinence, Signs or Symptoms of Bothersome Urinary Incontinence — 39; 85…
N/A N=120 Prophylactic Incisional Care in Obese Women at Cesarean
Wound Infections
Primary: Number of Participants With Composite Surgical Site Infection (SSI) or Other Wound Complication. — 5; 3 Participants — p=0.72
N/A N=710 Uphold LITE Post-Market Surveillance Study
Pelvic Organ Prolapse
Primary: Primary Efficacy Endpoint - Number of Participants With Composite Anatomic and Symptomatic Success at 36 Months — 201; 389; 199; 384 Participants — p=0.056